Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Cancer - 1 Nov 2017

Sherman Eric J, Dunn Lara A, Ho Alan L, Baxi Shrujal S, Ghossein Ronald A, Fury Matthew G, Haque Sofia, Sima Cami S, Cullen Grace, Fagin James A, Pfister David G

Abstract excerpt

BACKGROUND: Patients with recurrent and/or metastatic, radioactive iodine-refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase inhibitor, is approved by the US Food and Drug Administration for the treatment of radioactive iodine-refractory thyroid carcinoma, although it demonstrated low response rates (12.2%) as a single agent in the first-line setting. The objective of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Niacinamide

Share to Phenylurea Compounds

Share to Radiation Tolerance

Share to Sirolimus

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 28662274
DOI: 10.1002/cncr.30861
PMCID: PMC5650535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.PMID 28662274Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Novel targeted therapies and immunotherapy for advanced thyroid cancers.Semantic proximity Read ↗

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.Semantic proximity Read ↗

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Semantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Semantic proximity Read ↗

Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review.Semantic proximity Read ↗

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Semantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.